Ozempic is approved by the FDA for adults with type 2 diabetes to lower blood sugar, along with diet and exercise, reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who also have heart disease, and lower the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease
Quality assurance requires batch-specific Certificates of Analysis verifying peptide purity, heavy metal limits, and microbiological safety
"Their prices are the best around
Addressing Tolerability Issues Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are the most common reasons for discontinuation
RESOLVE-IT is a RDBPCT (2:1), conducted in approximately 2000 patients, at 250 centers worldwide